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ABSTRACT
Background: Hyperarousal appears to play an important role in the development and
maintenance of posttraumatic stress disorder (PTSD) symptoms, but current evidence-
based treatments appear to address this symptom type less effectively than the other
symptom clusters. The Mantram Repetition Program (MRP) is a meditation-based interven-
tion that has previously been shown to improve symptoms of posttraumatic stress disorder
(PTSD) and may be especially helpful for hyperarousal. If MRP is an effective tool for
decreasing this often treatment-resistant symptom cluster, it may become an important
clinical tool.
Objective: The goal of this secondary analysis was to examine the effect of the MRP on
hyperarousal and other PTSD symptom clusters and to examine hyperarousal as a mediator
of treatment response.
Method: Secondary analyses were conducted on data from a randomized controlled trial in
which Veterans with PTSD (n = 173) were assigned to the MRP or a non-specific psychother-
apy control and assessed pre-treatment, post-treatment and 8 weeks after treatment
completion. The impact of the interventions on PTSD symptom clusters was examined,
and time-lagged hierarchical linear modelling was applied to examine alternative mediation
models.
Results: All PTSD symptom clusters improved in both treatments. MRP led to greater
reductions in hyperarousal at post-treatment (Hedge’s g = 0.57) and follow-up (Hedge’s
g = 0.52), and in numbing at post-treatment (Hedge’s g = 0.47). Hyperarousal mediated
reductions in the composite of the other PTSD symptom clusters. Although the reverse
model was significant as well, the effect was weaker in this direction.
Conclusion: Interventions focused on the management of hyperarousal may play an impor-
tant role in recovery from PTSD. The MRP appears efficacious in reducing hyperarousal, and
thereby impacting other PTSD symptom clusters, as one pathway to facilitating recovery.
Abordando la hipervigilancia: El Programa de Repetición de Mantras
para el TEPT en veteranos estadounidenses
Antecedentes: La hipervigilancia parece desempeñar un papel importante tanto en el
desarrollo como en la mantención de los síntomas del trastorno de estrés postraumático
(TEPT), pero los tratamientos basados en la evidencia actuales parecen abordar esta
sintomatología de una manera menos efectiva que otras constelaciones de síntomas. El
Programa de Repetición de Mantras (MRP por sus siglas en inglés) es una intervención
basada en la meditación que previamente ha demostrado que puede mejorar los síntomas
del TEPT y que pudiese ser beneficiosa específicamente en la hipervigilancia Si el MRP fuese
una técnica efectiva para disminuir este síntoma que frecuentemente es resistente al
tratamiento, se podría convertir en una herramienta clínica importante.
Objetivo: El objetivo de este análisis secundario fue el evaluar el efecto del MRP sobre la
hipervigilancia y otras constelaciones sintomáticas del TEPT, y el de evaluar cómo la
hipervigilancia media la respuesta al tratamiento.
Método: Se realizaron análisis secundarios sobre la base de datos de un ensayo clínico
controlado aleatorizado en el cual un grupo de veteranos con TEPT (n = 173) fueron
asignados al programa MRP o a un grupo control de psicoterapia inespecífica. Se evaluaron
antes del tratamiento, inmediatamente luego del tratamiento, y a las ocho semanas poster-
iores de concluir el tratamiento. Se evaluó el impacto de las intervenciones sobre las
constelaciones de síntomas del TEPT, y se aplicó un modelo linear jerárquico de tempor-
alidad retrasada para evaluar modelos alternativos de mediación.
Resultados: Todas las constelaciones sintomáticas del TEPT mejoraron con ambos trata-
mientos. El MRP condujo a mayores reducciones en la hipervigilancia inmediatamente luego
del tratamiento (g de Hedge = 0,57) y en el seguimiento (g de Hedge = 0,52), así como en la
insensibilidad inmediatamente luego del tratamiento (g de Hedge = 0,47). La hipervigilancia
medió las reducciones en la integración de otras constelaciones sintomáticas del TEPT.
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A pesar de que el modelo de regresión también fue significativo, el efecto fue más débil en
esta dirección.
Conclusión: Las intervenciones enfocadas en el manejo de la hipervigilancia podrían
desempeñar un papel importante en la recuperación del TEPT. El MRP impresiona ser eficaz
en reducir la hipervigilancia, generando de esta manera un impacto sobre otras constela-
ciones sintomáticas del TEPT, constituyéndose en un camino para facilitar la recuperación.
以高唤起为靶点：针对美国退伍军人创伤后应激障碍的念诵疗法
背景：高唤起似乎在创伤后应激障碍（PTSD）症状的发展和维持中呈现出了重要作用，
但目前针对这一症状的循证治疗似乎不如其他症状簇那么有效。 念诵疗法（Mantram
Repetition Program, MRP）是一种基于冥想的干预措施，此前已被证明可改善创伤后应激
障碍（PTSD）的症状，且可能尤其对高唤起有用。如果MRP可有效降低这种经常治疗无
效的症状簇水平，那么它就可能成为一个重要的临床工具。
目的：此二次分析的目的是考查MRP对高唤起和其他PTSD症状簇的效果，并考查高唤起
是否是治疗反应的一个中介变量。
方法：对来自一个随机对照试验的数据进行了二次分析，这个试验将173名患有PTSD的退
伍军人分为MRP组或非特异性心理治疗对照组，并分别在治疗前、治疗后和治疗完成后8
周进行评估。考查了对创伤后应激障碍症状簇进行干预的影响，并应用时滞性多层线性
模型来检验备择中介模型。
结果：所有PTSD症状簇在两种治疗中都有所改善。 在MRP组的治疗中，高唤起症状在治
疗后（Hedge’s g= 0.57）和随访中（Hedge’s g= 0.52）大幅降低，麻木水平在治疗后
（Hedge’s g= 0.47）明显下降。高唤起中介了其他PTSD症状簇水平的降低。虽然逆向模
型也显著，但效应更弱。
结论：聚焦于高唤起治疗的干预措施可能在创伤后应激障碍的恢复中发挥重要作用。 MRP
可有效降低高唤起水平，从而影响到其他PTSD症状簇，可作为促进康复的一种途径。
More than half (56.6%) of USA (US) veterans returning
from Operation Enduring Freedom/Operation Iraqi
Freedom (OEF/OIF) endorse exposure to traumatic
events and more than a third (36.9%) meet criteria for
posttraumatic stress disorder (PTSD; Baker et al., 2009),
creating tremendous additional demand for effective
PTSD treatment strategies to meet the needs of this
newest cohort of combat veterans. Although well-
established, efficacious psychotherapies for PTSD exist,
30–51% of veterans do not make clinically meaningful
improvement, and 28–40% do not experience remission
under current best practice (Steenkamp, Litz, Hoge, &
Marmar, 2015). PTSD is a multi-faceted disorder, and
any given treatment may not address all aspects of the
disorder. For example, Prolonged Exposure (PE) most
consistently impacts re-experiencing and avoidance
(Schnurr & Lunney, 2015), and Cognitive Processing
Therapy (CPT) has been observed to impact re-
experiencing and emotional numbing to a greater extent
than avoidance or hyperarousal (Monson et al., 2006).
Similarly, Zayfert and DeViva (2004) found that, despite
large decreases in clinician-rated symptoms, 41% of
patients completing cognitive behavioural therapy
(CBT) for PTSD continued to manifest clinically signifi-
cant insomnia, anger and irritability, which may be
explained by the persistence of hyperarousal. Thus,
there is a clinical need for treatments that effectively
reduce hyperarousal.
PTSD Hyperarousal 
Symptoms
PTSD Re-
experiencing, 
Avoidance and 
Numbing Symptoms
Time
a b
c/c’
Figure 1. Proposed mediation model. a = effect of predictor on proposed mediator; b = effect of proposed mediator on
outcome when controlling for predictor; c’ = direct effect of predictor when controlling for proposed mediator. The indirect path
of the predictor on the outcome via the proposed mediator occurs via the product of paths a and b.
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Hyperarousal is of clinical importance; for exam-
ple, those who report hyperarousal to be their most
bothersome symptom at baseline improve less in
overall distress over time than other trauma-exposed
individuals (Schell, Marshall, & Jaycox, 2004).
Further, several models of PTSD underscore the
importance of hyperarousal in the maintenance of
the disorder. Consistent with a cognitive conceptua-
lization of the disorder, individuals with PTSD are
more likely to interpret symptoms of physiological
arousal as threatening (Lang, Kennedy, & Stein,
2002), forming a vicious cycle of reactivity to one’s
fear response (Marshall, Miles, & Stewart, 2010).
Extinction models, on the other hand, posit that fear-
related physiological arousal may act as a conditioned
response that maintains reactivity to conditioned sti-
muli (i.e., trauma-related cues; Careaga, Girardi, &
Suchecki, 2016). PTSD, therefore, may result from
the failure to extinguish these contingencies
(Blechert, Michael, Vriends, Margraf, & Wilhelm,
2007; Rothbaum & Davis, 2003).
Extant literature suggests the need for novel inter-
ventions, particularly those to hyperarousal symptoms.
A growing number of veterans pursue complementary
(i.e. in combination with other approaches, also
referred to as adjunctive), alternative (i.e. in place of
other treatments) and integrative (i.e. as part of
a holistic recovery plan that focuses on restoring well-
being) therapies to address their clinical needs (Goertz
et al., 2013). The Mantram Repetition Program (MRP)
is comprised of a set of portable, meditation-based tools
(mantram repetition, one-pointed attention and slow-
ing down) to help participants train attention and reg-
ulate emotions (Wadlinger & Isaacowitz, 2011). A key
component of theMRP is themantram, a short spiritual
phrase or prayer to be repeated frequently to initiate the
relaxation response. With practice, it is suggested, par-
ticipants develop the ability to manage distressing
thoughts and emotions. In an initial randomized con-
trolled trial, MRP was evaluated as a complement to
treatment-as-usual consisting of the case and medica-
tionmanagement (MRP+TAU) as compared to or TAU
alone. MRP+TAU led to significant improvements in
PTSD symptoms; the strongest observed effects were on
symptoms of hyperarousal (Bormann, Thorp,
Wetherell, Golshan, & Lang, 2013). The MRP also has
been associated with moderate-to-large reductions in
insomnia with concurrent reductions in PTSD symp-
toms in veterans (Beck et al., 2017; Bormann et al.,
2018). These findings are consistent with previous
work that suggests that mantra-based meditation prac-
tices are associated with reduced physiological arousal
(Lang et al., 2012).
The data used herein were drawn from
a randomized, controlled trial of MRP as compared
to Present-Centred Therapy, a non-specific psy-
chotherapy control; the purpose of the trial was an
evaluation of the efficacy of MRP (refer to Bormann
et al., 2018). MRP resulted in significantly greater
improvements in overall PTSD severity at post-
treatment and 2-month follow-up (Bormann et al.,
2018), but did not examine cluster-specific changes.
The current secondary analysis aimed to explore
whether MRP particularly targets hyperarousal
(Bormann et al., 2013). An additional aim was to
examine hyperarousal as a mediator of improvement
in the other PTSD symptom clusters. The implication
of this work would be the identification of a viable
strategy for addressing hyperarousal, a hard-to-treat
symptom, and potentially advancing care for PTSD.
1. Method
1.1. Participants
This study involved secondary analysis of data pre-
viously collected from 173 veterans enrolled in a multi-
site randomized controlled trial comparing individually
delivered MRP to individually delivered Present-
Centred Therapy (PCT) (NCT-01506323). Results of
primary outcomes and subject flow in this trial have
been reported previously (Bormann et al., 2018).
Inclusion criteria were being age 18 or older, diagnosed
with PTSD secondary to a military-related trauma, sta-
bilized on psychotropic medications for at least 2
months prior to enrolment, and not concurrently par-
ticipating in other PTSD-related therapies. Exclusion
criteria were active substance abuse, having severe sui-
cidal ideation, psychosis, dementia, or untreated bipolar
disorder, and having engaged in any complementary
therapies in the past 6 months.
The average age in this sample was 48.90 years
(SD = 14.54) and more than a third (n = 61, 35.3%)
reported an income of less than $20,000 annually.
More than two-thirds of this sample (n = 119,
68.8%) identified their race as White, 13 (7.5%)
identified as an American Indian or Alaskan
Native, 7 (4.0%) as Asian or Asian American, 28
(16.2%) as Black or African American, and 10
(5.8%) as Native Hawaiian or a Pacific Islander
(participants could identify with more than one
racial or ethnic group). Further, 30 (17.3%)
described themselves as Hispanic or Latino(a).
Most of the sample identified as male (n = 147,
85.0%). Approximately one third (n = 58, 33.5%)
reported they were currently married or in
a relationship with a partner. Nearly two-thirds of
the sample (n = 113, 65.3%) reported current use of
psychiatric medications for PTSD.
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1.2. Measures
1.2.1. Clinician-administered PTSD scale for
DSM-IV (CAPS)
The CAPS (Blake et al., 1995) is a structured clinician-
administered interview to assess for the presence and
severity of PTSD; it is considered the gold-standard
diagnostic interview for PTSD. CAPS assessment
items assess the frequency and severity of DSM-IV-
TR PTSD symptoms. The CAPS demonstrates good
internal consistency interrater reliability, and excellent
convergent validity (Weathers, Keane, & Davidson,
2001). Cronbach’s α was 0.91 in this sample.
Participants were assessed using the CAPS at baseline,
following completion of treatment, and at 8-week fol-
low-up. CAPS subscale scores are presented herein
because of our interest in differentiating among clus-
ters; for results related to the CAPS total score, the
reader is referred to Bormann et al. (2018), which
reports the main study outcomes.
1.2.2. Posttraumatic checklist-military version
(PCL-M)
The PCL-M (Weathers, Litz, Herman, Huska, & Keane,
1993) is a 17-item self-report inventory assessing DSM-
IV PTSD symptoms. Respondents rate each item from 1
(‘not at all’) to 5 (‘extremely’) to describe a combination of
the frequency and severity of each symptom, with higher
scores indicating worse symptoms. The military version
phrases items specifically in relation to military-related
experiences. It demonstrates good internal consistency
and convergent validity (Wilkins, Lang, & Norman,
2011). Cronbach’s α was 0.92 in this sample. For media-
tion analyses, re-experiencing, avoidance, and numbing
were summed to create a composite score. Participants
completed the PCL-M at baseline, weekly during the
intervention, at post-treatment, and at 8-week follow-up.
PTSD symptom clusters used in this study were
those recommended by King, Leskin, King, and
Weathers (1998) and were used to more closely
approximate DSM 5th Version (DSM-5) criteria for
the disorder as this study was conducted before its
release; re-experiencing and hyperarousal are
unchanged from the DSM-IV scores. Four symptom
clusters were used: (1) reexperiencing (CAPS, α = .78,
.77, .77 for pre-treatment, post-treatment, and 8-week
follow-up, respectively; PCL-M, α = .89, .82, .90); (2)
avoidance (CAPS, α = .60, .56, .54; PCL-M, α = .83,
.84, .91); (3) emotional numbing (CAPS, α = .63, .61,
.65; PCL-M, α = .79, .79, .79); and (4) hyperarousal
(CAPS, α = .61, .63, .60; PCL-M, α = .79, .79, .79).
1.3. Procedures
Approval was obtained from the VA Human Research
Protection Programmes at the two participating institu-
tions, the Bedford VA Medical Centre and the VA San
Diego Healthcare System. Veterans were recruited using
flyers and provider referrals. Consenting participants
were assessed using a structured interview administered
by a blind assessor and self-report measures. Following
the completion of the initial assessment, participantswere
randomly assigned into either the experimental condition
(MRP) or the control (PCT). Assessments occurred again
at the end of treatment and 2 months after treatment
completion.Methodology, including randomization pro-
cedures, is described in detail in the parent manuscript
(Bormann et al., 2018). After randomization, the two
groups did not differ in terms of age, gender, race,
income, years of education, nor PTSD medication use.
1.4. Interventions
All participants received individual therapy delivered by
a trained clinician. The interventions were manualized
and delivered in eight weekly, 60-min sessions. MRP
teaches how to redirect attention, regulate emotion, and
elicit relaxation by silently and intermittently repeating
a self-selected, sacred word or phrase. Present-Centred
Therapy (PCT) is a non-specific psychotherapy control.
In each session, the therapist helps participants to iden-
tify challenges they are facing and to draw on their
personal wisdom and resources to address those pro-
blems. All sessions were recorded, and 15% were ran-
domly selected for review by an expert clinician; both
conditions were delivered with a high level of fidelity.
1.5. Data analytic plan
The data used in these analyses formed a multilevel,
hierarchical structure with repeated measures (base-
line, weekly during treatment, follow-ups) nested
within participants. For each model we tested, Level
1 data included the measures of PTSD collected at
each time point. Individual participants were the
Level 2 units. Thus, these data were appropriate for
hierarchical linear modelling. This approach is robust
against missing data and variable numbers of obser-
vations between participants (Raudenbush, 2001).
Missing data in our data set, because it is the final
analysed data set from the parent trial, were limited
to participants who did not have data for an entire
time point; our analytic plan allows us to use avail-
able data at each time point, even when another time
point is missing for a given individual. In the parent
RCT (Bormann et al., 2018), item-level missingness
was minimal, so multiple imputation was used to
estimate missing item responses in these rare cases.
Data were analysed with an intent-to-treat approach
in a multilevel modelling framework to aid a more
conservative estimation of treatment efficacy
(Heritier, Gebski, & Keech, 2003) while recognizing
the pragmatic challenges of longitudinal treatment
research with a clinical population of Veterans.
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To evaluate effects of treatment and condition on PTSD
symptom clusters, we used linear mixed-effects modelling
to analyse the effects of time, condition, and their interac-
tion; models included random intercepts and slopes of
time. Differences in outcomes were evaluated using the
between-groups Hedge’s g effect size. CAPS, the gold-
standard for PTSD assessment, was used for these analyses.
The PCL-M was used in mediation analyses, however,
because this measure was collected weekly and allowed
for demonstration of temporal precedence. We tested for
mediation by examining if the presence of the proposed
mediator, PCL hyperarousal, attenuated the effect of the
predictor (time) on the criterion variable, a composite of
re-experiencing, avoidance, and numbing (see Figure 1).
We used the methodology established by Bauer, Preacher,
and Gil (2006) and Kenny, Korchmaros, and Bolger
(2003). We evaluated models using the composite of the
non-hyperarousal symptoms as the outcome in each of the
treatment conditions. Using repeatedmeasures, we ‘lagged’
our proposed mediators to examine whether changes in
themediator at time t predicted the outcome variable at t+
1 (for example, see Aderka, Foa, Applebaum, Shafran, &
Gilboa-Schechtman, 2011; Bomyea et al., 2015; Donegan&
Dugas, 2012). We used the indirect effect, ab, as the effect
size in these analyses. Per Preacher and Kelley (2011), the
indirect effect can communicate both practical importance
and effect size.
2. Results
2.1. Descriptive statistics
Descriptive statistics are displayed in Table 1. The inter-
vention groups did not differ with respect to attrition.
At posttreatment, 22% had discontinued from MRP,
whereas 14% dropped PCT (χ2 = 1.92, p = 0.16). At
follow-up, 26% were lost from the MRP group as com-
pared with 15% in PCT (χ2 = 3.93, p = 0.07) (Bormann
et al., 2018). The parent RCT’s attrition analysis found
that only age differed between those who completed
(mean age = 50, SD = 14.59) and those who dropped
out of treatment (mean age = 43.88, SD = 13.41), F
(1,171) = 4.78, p < 0.05. Because age was not
differentially related to the treatment group, however,
we conclude that it is unlikely to affect the pattern of
symptom change associated with MRP vs PCT.
Total scores on the CAPS and PCL-M in this
sample have previously been reported (Bormann
et al., 2018). The omnibus between-group difference
on CAPS PTSD symptom measures was not signifi-
cant (Pillai’s Trace F(8, 149) = 0.05, p = 0.483). Also,
there were no baseline (i.e., prior to randomization,
prior to start of treatment), differences in PTSD clus-
ter scores on the CAPS and PCL-M (see Table 1).
2.2. Treatment effects on hyperarousal and other
symptom clusters
Results of linear mixed-effects models are presented
in Table 2. The fixed effect of time was significant for
all four symptom clusters as measured by the CAPS
(ps < 0.001) and the effect of condition was not
significant in any of the four models (0.067 ≤ ps ≤
0.958). The time x condition interaction was signifi-
cant for numbing (t(1,118.45) = −3.15, p = 0.002) and
hyperarousal (t(1,88.53) = −4.03, p < 0.001) but not
for re-experiencing (t(1,118.22) = −1.01, p = 0.316)
nor avoidance (t(1,124.22) = −1.02, p = 0.312).
To understand these interactions, we examined
between-group effect sizes, Hedges’ g (see Table 3).
Differences between MRP and PCT (i.e., the 95% con-
fidence interval did not contain 0) emerged for numb-
ing at post-treatment, g = 0.47, and for hyperarousal at
post-treatment, g = 0.57, and 8-week follow-up,
g = 0.52.
2.3. Mediational models
2.3.1. Hyperarousal as a mediator
We first examined whether change in hyperarousal
mediated change in the composite of the other three
symptom clusters (see Table 4). Within the MRP group,
time had significant effects on both the composite of re-
experiencing, avoidance and numbing (path c: B = −0.60,
SE = 0.08, p < 0.001) and hyperarousal (path a: B = −0.29,
Table 1. Descriptive statistics for PTSD symptoms.
Mantram Repetition Program Present-Centred Therapy
BL
CAPS (n = 89)
PCL (n = 85)
Post
CAPS (n = 69)
PCL (n = 68)
8WFU
CAPS (n = 65)
PCL (n = 61)
BL
CAPS (n = 84)
PCL (n = 79)
Post
CAPS (n = 72)
PCL (n = 70)
8WFU
CAPS (n = 71)
PCL (n = 66)
M SD M SD M SD M SD M SD M SD
CAPS Re-experiencing 21.90 7.65 14.58 8.74 13.27 8.89 21.36 6.90 16.46 9.10 15.26 10.35
Avoidance 10.66 3.74 7.19 4.22 6.76 4.36 10.05 3.40 8.22 4.69 6.61 5.47
Numbing 19.68 6.92 12.82 7.73 12.17 8.49 18.95 7.58 16.52 7.77 15.70 8.96
Hyperarousal 25.51 5.58 17.75 8.75 16.80 8.89 24.38 6.02 22.16 6.65 21.12 7.48
PCL Re-experiencing 16.56 4.43 12.69 4.91 12.77 4.90 15.80 4.34 13.67 4.51 13.14 5.24
Avoidance 7.59 2.07 5.72 2.43 5.77 2.43 7.15 2.12 6.59 2.60 5.97 2.68
Numbing 16.55 4.48 12.60 5.05 12.15 4.71 15.84 4.30 13.90 4.81 13.52 5.13
Hyperarousal 18.56 4.13 14.38 5.26 14.01 5.05 18.78 3.55 16.19 4.50 15.80 4.67
CAPS = Clinician-Administered PTSD Scale; PCL = Posttraumatic Checklist – Military Version; BL = Baseline; Post = Post-treatment; 8WFU = 8-week
Follow-up.
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SE = 0.04, p < 0.001). When the composite was regressed
onto time and hyperarousal simultaneously, the effects of
both time (path c’: B = −0.40, SE = 0.11, p < 0.001) and
hyperarousal (path b: B = 1.43, SE = 0.16, p < 0.001) were
significant. Based on these data, hyperarousal signifi-
cantly mediated improvements in the composite of the
other clusters (ab: B = −0.41; 95% CI [−0.56, −0.28]) in
the MRP group.
The Level 1 model regressing the composite score
on time in the PCT group indicated that symptoms
significantly decreased following PCT (path c: B =
−0.40, SE = 0.08, p < 0.001). Regressing hyperarousal
on time revealed significant improvements in hyper-
arousal (path a: B = −0.19, SE = 0.03, p < 0.001).
When modelled simultaneously to predict the com-
posite, the effect of hyperarousal remained significant
(path b: B = 1.53, SE = 0.15, p < 0.001), but the effect
of time did not (path c’: B = −0.12, SE = 0.13, p =
0.375). These results indicate that hyperarousal sig-
nificantly mediated change in the composite of the
other three symptom clusters (ab: B = −0.29; 95% CI
[−0.40, −0.19]) in the PCT group as well. Although
the effect observed in the MRP condition is numeri-
cally greater than the effect in the PCT condition, the
95% confidence intervals overlap indicating they do
not differ significantly in this sample.
2.3.2. Reverse models
Results of the reverse models for both treatment arms
are in Table 5. Within the MRP group, time had sig-
nificant effects on both hyperarousal (path c: B = −0.29,
SE = 0.04, p < 0.001) and the composite of the other
clusters (path a: B = −0.60, SE = 0.08, p < 0.001). When
regressing hyperarousal onto time and the composite
simultaneously, time (path c’: B = −0.17, SE = 0.05, p =
0.001) and the composite (path b: B = 0.28, SE = 0.05,
p < 0.001) both had significant effects. Based on these
data, the sum of the non-hyperarousal symptoms sig-
nificantly mediated improvements in hyperarousal
(path ab: B = −0.17; 95% CI [−0.23, −0.11]). This con-
fidence interval did not overlap between the original
and reverse models, indicating that the mediation effect
of hyperarousal on the other symptom types was greater
than the reverse in the MRP condition.
In the PCT condition, the Level 1 model regressing
hyperarousal on time indicated that hyperarousal sig-
nificantly decreased following PCT (path c: B = −0.19,
SE = 0.03, p < 0.001). Regressing the composite of the
other symptom clusters on time revealed significant
improvements in these symptoms (path a: B = −0.40,
SE = 0.08, p < 0.001). Modelled concurrently to predict
hyperarousal, the effect of the composite remained sig-
nificant (path b: B = 0.28, SE = 0.05, p < 0.001) as did the
effect of time (path c’: B = −0.17, SE = 0.06, p = 0.007).
These results suggested the non-hyperarousal symp-
toms significantly mediated change in hyperarousal
(path ab: B = −0.17; 95% CI [−0.18, −0.05]). However,
like the results observed in theMRP condition, this 95%
confidence interval does not overlap with the confi-
dence interval observed in the hypothesized original
model suggesting the mediation effect of hyperarousal
on the composite is greater than the reverse.
3. Discussion
This study evaluated the effect of a meditation-based
intervention, MRP, as compared to an active control
condition, PCT, on hyperarousal, a subset of PTSD
Table 2. Linear mixed-effects models.
Predictor B SE df t p LLCI ULCI
Outcome: CAPS–Re-experiencing
Time −0.48 0.06 118.22 −8.6 <0.001 −0.59 −0.37
Group −0.32 1.06 169.07 −0.31 0.761 −2.41 1.76
Time x Group −0.11 0.11 118.22 −1.01 0.316 −0.34 0.11
Outcome: CAPS–Avoidance
Time −0.25 0.03 124.22 −7.93 <0.001 −0.31 −0.19
Group −0.03 0.5 173.43 −0.05 0.958 −1.01 0.96
Time x Group −0.06 0.06 124.22 −1.02 0.312 −0.19 0.06
Outcome: CAPS–Numbing
Time −0.42 0.05 118.45 −9.10 <0.001 −0.51 −0.33
Group −1.36 1.04 168.08 −1.31 0.192 −3.4 0.69
Time x Group −0.29 0.09 118.45 −3.15 0.002 −0.46 −0.11
Outcome: CAPS–Hyperarousal
Time −0.42 0.05 88.53 −8.22 <0.001 −0.52 −0.32
Group −1.64 0.89 161.29 −1.84 0.067 −3.41 0.12
Time x Group −0.41 0.1 88.53 −4.03 <0.001 −0.61 −0.21
LLCI = lower limit of the 95% confidence interval; ULCI = upper limit of
the 95% confidence interval. CAPS = Clinician-Administered PTSD
Scale.
Table 3. Between-groups effect sizes.
Pre-treatment Post-treatment 8-week follow-up
CAPS–Re-experiencing −0.07 (−0.38, 0.23) 0.24 (−0.09, 0.58) 0.20 (−0.22, 0.63)
CAPS–Avoidance −0.71 (−0.47, 0.13) 0.23 (−0.11, 0.57) −0.02 (−0.46, 0.40)
CAPS–Numbing −0.10 (−0.40, 0.20) 0.47* (0.14, 0.82) 0.40 (−0.02, 0.84)
CAPS–Hyperarousal −0.19 (−0.50, 0.11) 0.57* (0.22, 0.91) 0.52* (0.09, 0.96)
*p ≤ 0.05 as demonstrated by the absence of 0 from the 95% confidence interval. Effect sizes are Hedge’s
g. CAPS = Clinician-Administered PTSD Scale.
Table 4. Multilevel mediation.
Path Predictor Outcome Estimate SE df t p
Present-Centred Therapy
c Time PCL-RAN −0.40** 0.08 68.24 −4.90 <0.001
a Time PCL-H −0.19** 0.03 53.44 −5.51 <0.001
b PCL-H PCL-RAN 1.53** 0.15 27.37 9.98 <0.001
c’ Time PCL-RAN −0.12 0.13 49.52 −0.90 0.375
Mantram Repetition Program
c Time PCL-RAN −0.60** 0.08 64.66 −7.29 <0.001
a Time PCL-H −0.29** 0.04 64.40 −7.15 <0.001
b PCL-H PCL-RAN 1.43** 0.16 55.76 9.14 <0.001
c’ Time PCL-RAN −0.40 0.11 80.41 −3.70 <0.001
*p ≤ 0.05, **p ≤ 0.05. PCL-RAN = Posttraumatic Checklist–Military
Version (PCL-M) composite of re-experiencing, avoidance, and numb-
ing factors; PCL-H = PCL, Hyperarousal Subscale.
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symptoms that is not well addressed by existing empiri-
cally supported PTSD treatments. Consistent with our
prior findings (Bormann et al., 2013), MRP was asso-
ciated with significantly greater change in hyperarousal
than PCT. MRP also resulted in more change in numb-
ing symptoms at post-treatment, but this effect was not
sustained. MRP did not outperform the control condi-
tion in relation to re-experiencing or avoidance. It
should be noted, however, that all symptom clusters
significantly improved for both treatments, which is
consistent with past studies that have demonstrated
that PCT is efficacious for the treatment of PTSD
(Frost, Laska, & Wampold, 2014). Further, mediational
models were applied to evaluate hyperarousal as
a driver of change in PTSD symptoms. As predicted,
change in hyperarousal mediated change in the aggre-
gate of the remaining PTSD symptom clusters. While
the reverse model was significant as well, the hyperar-
ousal model was stronger.
Although there is insufficient evidence to recommend
any complementary or alternative practice as a first-line
treatment for PTSD (Lang & Niles, 2019), these results
support the clinical application of MRP to target hyper-
arousal, which may be a useful complement to current
evidence-based approaches. Further, the mediation ana-
lysis suggests that improvements in hyperarousal may
spill over to target the disorder more broadly if MRP is
applied as an alternative approach. As with any emerging
intervention, however, providers should utilize appropri-
ate strategies to monitor clinical response and adjust the
treatment approach based on patient needs.
This work highlights the need for additional research.
Although this is the second study to show that MRP
targets hyperarousal, the mechanisms by which this
occurs are not well understood. Assessing other indices
of hyperarousal such as physiology or biomarkers could
allow us to better tease apart the contributions of actual
and perceived arousal. Further, the similarities to and
differences from other meditation-based approaches for
PTSD should be better elucidated. A recent PTSD study
showed that transcendental meditation, another mantra-
based practice, was not inferior to Prolonged Exposure
(PE) and outperformed health education (Nidich et al.,
2018). Although theory predicts that it toomight support
a reduction in physiological arousal (Lang et al., 2012),
such data are not yet available. Change in hyperarousal
has also been observed with yoga (Wells, Lang, Schmalzl,
Groessl, & Strauss, 2016) and compassion meditation
(Lang et al., 2019); investigators should be encouraged
to report data on symptom clusters to further our under-
standing of potential complementary uses of meditation.
Finally, MRP can be combined with other approaches in
several ways (e.g., sequential, parallel, integrated), but
data are lacking on the outcomes associated with various
approaches. Given the number of possible combinations,
it will be a methodological challenge to examine the
various programmes of care. This project included all
patients with PTSD, so the targeted application of MRP
to patients who have prominent or intractable symptoms
of hyperarousal has yet to be evaluated. Given that hyper-
arousal has previously demonstrated temporal prece-
dence naturalistically among civilians (Marshall, Schell,
Glynn, & Shetty, 2006), the possibility of early application
of MRP to prevent the development of PTSD could be
considered as well.
Results of this study should be interpreted within the
context of several limitations. This study used a sample
of US veterans diagnosed with military-related PTSD,
and these results may not generalize to other popula-
tions. Further, Dr Bormann has been the first to apply
MRP to PTSD, so allegiance effects are possible.We also
donot have data regarding the time since the occurrence
of the index traumatic event. Age moderates the rela-
tionship between coping and distress, possibly due to
increased vulnerability to stressors following trauma
(Littleton, Horsley, John, & Nelson, 2007), so including
time since trauma as a covariate may have affected our
results. Additionally, the parent RCT from which this
secondary analysis is drawn used a conservative power
estimation (i.e., 80% power to detect medium effect on
CAPS, using one time point instead of two resulting in
a needed sample size of 150 per treatment arm); how-
ever, it did not reach its initial recruitment goal and
therefore the current analysis may be underpowered. In
spite of this, we have replicated past results (Bormann
et al., 2013), although it is possible that groupdifferences
in the other clusters may have been detected with
a larger sample. Additionally, this secondary analysis
did not include a sensitivity analysis to account for
possible confounding variables such as past treatment
history; a larger sample size and a priori identification of
possible confounders are encouraged in future studies.
Finally, the study was implemented before the release of
DSM-5, so it is possible that these results would not
generalize to the current diagnostic system.
Consistent with trends towards personalized med-
icine, optimal psychotherapeutic treatments may
need to vary based on an individual’s unique presen-
tation (Friedman, 2014). This may be especially true
for veterans with hyperarousal or related symptoms
(e.g., irritability, sleep difficulties) that remain even
Table 5. Reverse multilevel mediation.
Path Predictor Outcome Estimate SE df t p
Mantram Repetition Program
c Time PCL-H −0.60 0.04 64.40 −7.15 <0.001
a Time PCL-RAN −0.60 0.08 64.66 −7.29 <0.001
b PCL-H PCL-H 0.29 0.03 142.65 10.54 <0.001
c’ Time PCL-H −0.17 0.06 46.08 −2.84 0.007
Present-Centred Therapy
c Time PCL-H −0.19 0.03 53.44 −5.51 <0.001
a Time PCL-RAN −0.40 0.08 68.24 −4.90 <0.001
b PCL-H PCL-H 0.28 0.05 107.44 5.10 <0.001
c’ Time PCL-H −0.12 0.07 21.56 −1.70 0.105
PCL-RAN = Posttraumatic Checklist–Military Version (PCL-M), composite
of re-experiencing, avoidance, and numbing factors; PCL-H = PCL,
Hyperarousal Subscale.
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after significant improvements in other PTSD symp-
toms or when hyperarousal-related symptoms pre-
vent engagement in trauma treatment. Indeed, our
study is consistent with others that have noted the
potential for improving overall PTSD treatment out-
comes by reducing hyperarousal symptoms (Doron-
LaMarca et al., 2015). MRP appears to be a useful
strategy for reducing PTSD-related hyperarousal and
would have reasonable application as an alternative
or complementary treatment for PTSD in veterans.
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